Radiopharm Theranostics Limited (AU:RAD) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Radiopharm Theranostics has received ethics approval in Australia to initiate a Phase 1 clinical trial of their innovative cancer treatment, 177Lu-RAD202, targeting HER2-positive metastatic solid tumors. This trial aims to explore the safety and clinical activity of the treatment, offering a potential new strategy for patients resistant to current therapies. The study underscores Radiopharm’s commitment to addressing unmet medical needs in oncology.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.